Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy
Executive summary: Karmanos Cancer Institute started administering the FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) to eligible metastatic pancreatic cancer patients on August 31, 2026. This is the first clinical deployment of a KRAS‑targeted therapy in pancreatic cancer, a malignancy with few effective options, potentially improving outcomes and encouraging wider adoption of precision oncology.
Who is involved: Barbara Ann Karmanos Cancer Institute, the drug’s developer (implied by the FDA approval), patients with KRAS G12C‑mutated metastatic pancreatic cancer, and the FDA as the approving authority.
Likely next: Karmanos will collect real‑world efficacy and safety data; the FDA may require a post‑marketing Phase 4 study report by late 2027; payers are expected to issue coverage decisions within the next six months.
The Barbara Ann Karmanos Cancer Institute in Detroit announced on August 31, 2026 that it will now provide daraxonrasib (Rasonque) to patients with metastatic pancreatic cancer harboring the KRAS G12C mutation. The drug received FDA approval earlier in 2026 based on the RASolute 302 trial, which showed a measurable improvement in progression‑free survival compared with standard chemotherapy. By adding this targeted option, Karmanos expands the therapeutic arsenal for a disease with limited effective treatments and sets a precedent for community‑based adoption of KRAS‑directed agents.
Timeline
- — Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer (PR Newswire)
Analysis — what this means
Likely next events
- Karmanos plans to publish initial real‑world outcome data from the daraxonrasib program by Q1 2027.
- The FDA has requested a post‑marketing Phase 4 safety and overall survival report to be submitted by December 31, 2027.
- Medicare is anticipated to issue a national coverage determination for daraxonrasib in pancreatic cancer by March 2027.
Sectors affected
- Oncology drug market
- Pancreatic cancer therapeutics
- Precision medicine companion diagnostics
Regulatory implications
- FDA label restricts use to patients with confirmed KRAS G12C mutation via an approved companion diagnostic.
- Post‑marketing Phase 4 trial required to assess overall survival and long‑term safety; results due end‑2027.
- Any off‑label use will trigger additional FDA scrutiny and possible enforcement action.
Historical parallels
- FDA approval of sotorasib (Lumakras) for KRAS G12C‑mutated non‑small cell lung cancer in May 2021.
- FDA approval of adagrasib for KRAS G12C‑mutated NSCLC in December 2022.
Sources
- Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer — PR Newswire
Related cases
- FDA clears Caliway's CBL-514 combo with tirzepatide for Phase 2 trial as pivotal Phase 3 SUPREME-01 starts enrollment
- FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeutics
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
- Karmanos Cancer Institute launches a community‑focused cancer seminar series in Detroit to boost public engagement and awareness
- AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy